Affimed N.V. (NASDAQ:AFMD) – Research analysts at Leerink Swann raised their FY2017 earnings per share (EPS) estimates for Affimed N.V. in a report issued on Tuesday. Leerink Swann analyst M. Schmidt now forecasts that the biopharmaceutical company will post earnings of ($0.84) per share for the year, up from their prior estimate of ($0.85). Leerink Swann also issued estimates for Affimed N.V.’s Q4 2017 earnings at ($0.20) EPS and FY2018 earnings at ($0.61) EPS.
COPYRIGHT VIOLATION WARNING: “Leerink Swann Comments on Affimed N.V.’s FY2017 Earnings (AFMD)” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.themarketsdaily.com/2017/11/12/leerink-swann-comments-on-affimed-n-v-s-fy2017-earnings-afmd.html.
Several other equities analysts have also weighed in on AFMD. Jefferies Group LLC restated a “hold” rating and set a $2.50 target price on shares of Affimed N.V. in a report on Thursday, July 27th. ValuEngine downgraded Affimed N.V. from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
Affimed N.V. (AFMD) opened at $2.00 on Friday. Affimed N.V. has a 1-year low of $1.65 and a 1-year high of $2.95. The company has a quick ratio of 6.65, a current ratio of 6.43 and a debt-to-equity ratio of 0.14.
A number of hedge funds have recently added to or reduced their stakes in AFMD. Creative Planning grew its position in Affimed N.V. by 7.7% during the second quarter. Creative Planning now owns 70,000 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 5,000 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Affimed N.V. during the second quarter worth about $144,000. Finally, Nationwide Fund Advisors grew its position in Affimed N.V. by 4.6% during the second quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock worth $1,038,000 after buying an additional 22,172 shares in the last quarter. 42.34% of the stock is currently owned by institutional investors and hedge funds.
About Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.